Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.57 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.57 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.57 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.57 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | XDH | P47989 | 1/20 | 0.57 |
| ▸ | G6PD | P11413 | 1/20 | 0.50 |
| ▸ | AKT2 | P31751 | 3/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930055 | 0.80 | HSD17B10 (0.56) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL11903083 | 0.80 | CYP3A4 (0.53) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL3661701 | 0.80 | PI4KA (0.57) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL6749169 | 0.76 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL532653 | 0.76 | HIF1A (0.49) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL24292928 | 0.76 | HSD17B10 (0.47) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL7073449 | 0.74 | HTT (0.56) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL4419598 | 0.74 | PAK1 (0.60) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL5433393 | 0.73 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL30295447 | 0.73 | HSD17B10 (0.53) | PI4KAPI4K2BPI4K2API4KBLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513928-B1 | A BANK OF STEM CELLS FOR PRODUCING CELLS FOR TRANSPLANTATION HAVING HLA ANTIGENS MATCHING THOSE OF TRANSPLANT RECIPIENTS, AND METHODS FOR MAKING AND USING SUCH A STEM CELL BANK | ADVANCED CELL TECH INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20190225937-A1 | BANK OF STEM CELLS FOR PRODUCING CELLS FOR TRANSPLANTATION HAVING HLA ANTIGENS MATCHING THOSE OF TRANSPLANT RECIPIENTS AND METHODS FOR MAKING AND USING SUCH A STEM CELL BANK | ADVANCED CELL TECH INC (US) | 2019-07-25 | — | — | US | disclosed |
| US-20130276154-A1 | Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank | ADVANCED CELL TECHNOLOGY, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2008100447-A2 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| EP-1513928-A2 | A BANK OF STEM CELLS FOR PRODUCING CELLS FOR TRANSPLANTATION HAVING HLA ANTIGENS MATCHING THOSE OF TRANSPLANT RECIPIENTS, AND METHODS FOR MAKING AND USING SUCH A STEM CELL BANK | Advanced Cell Technology, Inc. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040091936-A1 | Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank | ADVANCED CELL TECHNOLOGY, INC. | 2004-05-13 | — | — | US | disclosed |
| WO-2003100018-A2 | A BANK OF STEM CELLS FOR TRANSPLANTATION | ADVANCED CELL TECHNOLOGY, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | PI4KA 267/4885PI4K2B 740/4885PI4K2A 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.